Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia

Int J Tuberc Lung Dis. 2002 Jul;6(7):573-9.


Setting: Three districts of Oromia Region in Arzi Zone, Ethiopia.

Objectives: To determine the rate of defaulting from directly observed treatment, short course (DOTS) for tuberculosis and identify associated factors.

Design: A case control study. Records of 1367 new tuberculosis patients put on DOTS during a period of 30 months (1 July 1997-31 December 1999) were reviewed to determine the defaulting rate. Cases were defaulters and controls were selected by paired matching of sex and age using the lottery method. All study subjects were actively traced and interviewed by trained interviewers using a pre-tested structured questionnaire.

Results: The overall rate of defaulting from DOTS was calculated to be 11.3%, while the rate in sputum smear-positive cases was 11.6%. Defaulting was highest (81%) during the continuation phase of treatment. Medication side effects were significantly associated with defaulting (OR = 4.20, 95% CI 1.51-11.66), while adequate knowledge and family support were found to be possible protective factors (OR = 0.04, 95% CI 0.02-0.1 and OR = 0.19, 95% CI 0.08-0.46, respectively).

Conclusions: Major factors contributing to high rates of defaulting were found to be lack of family support, inadequate knowledge about treatment duration and medication side effects. Control programmes that take these factors into consideration should be successful in reducing defaulting.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Ethiopia / epidemiology
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Patient Compliance / statistics & numerical data*
  • Patient Dropouts / statistics & numerical data*
  • Patient Education as Topic*
  • Risk Factors
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / epidemiology


  • Antitubercular Agents